Boston Scientific reported softer-than-expected 4Q guidance and highlighted a challenging year amid a cybersecurity incident that trimmed sales growth by about 300 basis points. While Q3 revenue beat consensus, both the 4Q outlook and 2027 cycle concerns weighed on the stock, which fell to a new 52-week low. The company reiterated a long-range plan to stabilize and grow through investments and an eventual rebound in 2028–2029, with a potential Penumbra acquisition shaping near-term optionality.
Boston Scientific disclosed a cybersecurity incident disrupting global manufacturing and order shipments, signaling a material impact to Q3 and full-year 2026 results. The scope and remediation timeline remain uncertain, raising near-term downside risk to revenue, backlog, and margins. Updated guidance or earnings impact will likely follow as the company completes its assessment.
Boston Scientific disclosed a cybersecurity incident that disrupted its global operations, including order-processing and shipping systems. The lack of detail on the cause or remediation timeline adds near-term uncertainty to revenue and delivery timelines. Investors should monitor updates on remediation progress and any impact to guidance.
Boston Scientific trimmed its annual profit forecast after signaling ongoing weakness in the Watchman left atrial appendage closure device business. The revision suggests the Watchman headwinds will weigh on near-term margins and sentiment, with investors awaiting clearer evidence of turning the device's demand or stronger replacement catalysts.
Boston Scientific disclosed board approval of a company-wide restructuring to cut costs and strengthen growth prospects. The Monday regulatory filing offered few specifics on savings targets or timelines. If executed well, the plan could improve margins and cash flow over the next 12–24 months, though near-term earnings may face restructuring charges and execution risk.
Boston Scientific shares dropped about 12% to a multi-year low after flagging declining usage of its heart-disease device. The comments suggest softer utilization in a core franchise, raising near-term revenue and margin concerns if volumes do not stabilize. Investors will focus on any guidance updates, adoption trends, and potential competitive or pricing implications.
